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A pragmatic approach to the design and
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Michael Cole1*, Deborah Stocken1, Christina Yap2
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The Continual Reassessment Method (CRM) is not
widely used in early phase dose finding trials partly
because the logistics of development and implementa-
tion are perceived as complex and time consuming.
Details are presented of the steps involved when design-
ing such a trial using an adaptation of a Bayesian CRM
calibration algorithm proposed by Cheung [1].
In addition to clinician centred parameters including
target toxicity probability and number of test doses, the
Bayesian CRM requires specification of the prior prob-
ability of toxicity associated with each of the test doses
and the prior SD of the single model parameter.
Cheung’s simple pragmatic approach is used to aid
selection of these parameters.
Competing designs are assessed in terms of risk-adjusted
accuracy and trial specific requirements including the
mean number of patients treated above the maximum
tolerated dose. Performance measures are estimated by
Monte Carlo simulation across a range of scenarios chosen
solely upon the target toxicity level and the number of test
doses.
We demonstrate that following this pragmatic
approach to CRM design calibration, design of CRM
trials need not be overly complex or time-consuming.
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